Han-Xin Lin1,2, Jenny Sjaarda1, Jocob Dyck1, Randa Stringer1, Chris Hillis3, Maria Harvey2, Ronald Carter1,2, Peter Ainsworth4,5, Brian Leber3, Guillaume Pare1,2,6,7,8,9, Bekim Sadikovic1,4,5. 1. Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. 2. Hamilton Regional Laboratory Medicine Program, Hamilton Health Science, Hamilton, ON, Canada. 3. Department of Oncology, McMaster University, Juravinski Hospital, Hamilton, ON, Canada. 4. Department of Pathology and Laboratory Medicine, Western University, London, ON, Canada. 5. Molecular Genetics Laboratory, London Health Sciences Centre, London, ON, Canada. 6. Population Health Research Institute, Hamilton Health Sciences, McMaster University; McMaster University, Hamilton, ON, Canada. 7. Population Genomics Program, Chanchlani Research Centre, McMaster University; McMaster University, Hamilton, ON, Canada. 8. Department of Clinical Epidemiology and Biostatistics, McMaster University; McMaster University, Hamilton, ON, Canada. 9. Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.
Abstract
OBJECTIVES: Achieving a major molecular response (MMR) is the goal of imatinib therapy for chronic myeloid leukemia. However, the association between gender, BCR-ABL transcript type, and age with MMR is not well understood and often controversial. METHODS: We retrospectively analyzed 166 patients who have been treated with imatinib for up to 10 yr. RESULTS: Men had a lower MMR rate than women (63.3% vs. 81.6%, P = 0.006) and a shorter time to relapse (median 354 vs. 675 d, P = 0.049), while patients with b3a2 or with both b3a2 and b2a2 break point transcripts had higher MMR rate than those with b2a2 (81.8%, 77.1% vs. 60.7%, P = 0.023 for b3a2 vs. b2a2, P = 0.043 for both vs. b2a2). A striking difference was found between men with b2a2 and women with both b2a2 and b3a2 in terms of MMR rate (43.8% vs. 88.9%), MMR rate within 6 months (7.1% vs. 62.5%) and the time to MMR (median d 493 vs. 159, P = 0.036). CONCLUSIONS: Both gender and BCR-ABL transcript, but not age, were significantly associated with the molecular response. Men with b2a2 represent a less favorable group in their response to imatinib treatment and may need alternative therapy regimen and closer monitoring.
OBJECTIVES: Achieving a major molecular response (MMR) is the goal of imatinib therapy for chronic myeloid leukemia. However, the association between gender, BCR-ABL transcript type, and age with MMR is not well understood and often controversial. METHODS: We retrospectively analyzed 166 patients who have been treated with imatinib for up to 10 yr. RESULTS:Men had a lower MMR rate than women (63.3% vs. 81.6%, P = 0.006) and a shorter time to relapse (median 354 vs. 675 d, P = 0.049), while patients with b3a2 or with both b3a2 and b2a2 break point transcripts had higher MMR rate than those with b2a2 (81.8%, 77.1% vs. 60.7%, P = 0.023 for b3a2 vs. b2a2, P = 0.043 for both vs. b2a2). A striking difference was found between men with b2a2 and women with both b2a2 and b3a2 in terms of MMR rate (43.8% vs. 88.9%), MMR rate within 6 months (7.1% vs. 62.5%) and the time to MMR (median d 493 vs. 159, P = 0.036). CONCLUSIONS: Both gender and BCR-ABL transcript, but not age, were significantly associated with the molecular response. Men with b2a2 represent a less favorable group in their response to imatinib treatment and may need alternative therapy regimen and closer monitoring.
Authors: Hayeon Noh; Su Young Jung; Jae-Yong Kwak; Sung-Hyun Kim; Suk Joong Oh; Dae Young Zang; Suhyun Lee; Hye Lin Park; Dae Jin Jo; Jae Soo Shin; Young Rok Do; Dong-Wook Kim; Jangik I Lee Journal: Cancer Med Date: 2018-03-25 Impact factor: 4.452
Authors: Mohammad A J Abdulla; Prem Chandra; Susanna El Akiki; Mahmood B Aldapt; Sundus Sardar; Ammar Chapra; Abdulqadir J Nashwan; Claudio Sorio; Luisa Tomasello; Christian Boni; Mohamed A Yassin Journal: Cancer Control Date: 2021 Jan-Dec Impact factor: 3.302